Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | Zendy

Paul K. Paik | Zendy; Enriqueta Felip | Zendy; R. Veillon | Zendy; Hiroshi Sakai | Zendy; Alexis B. Cortot | Zendy; Marina Chiara Garassino | Zendy; Julien Mazières | Zendy; Santiago Viteri | Zendy; Hélène Senellart | Zendy; Jan P. van Meerbeeck | Zendy; Jo Raskin | Zendy; Niels Reinmuth | Zendy; Pierfranco Conté | Zendy; Dariusz M. Kowalski | Zendy; Byoung Chul Cho | Zendy; Jyoti D. Patel | Zendy; Leora Horn | Zendy; Frank Griesinger | Zendy; JiYoun Han | Zendy; YoungChul Kim | Zendy; GeeChen Chang | Zendy; ChenLiang Tsai | Zendy; James ChihHsin Yang | Zendy; Yuh-Min Chen | Zendy; Egbert F. Smit | Zendy; Anthonie J. van der Wekken | Zendy; Terufumi Kato | Zendy; Dilafruz Juraeva | Zendy; Christopher Stroh | Zendy; Rolf Bruns | Zendy; Josef Straub | Zendy; Andreas Johne | Zendy; J. Scheele | Zendy; John V. Heymach | Zendy; Xiuning Le | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

Author(s) -

Paul K. Paik,

Enriqueta Felip,

R. Veillon,

Hiroshi Sakai,

Alexis B. Cortot,

Marina Chiara Garassino,

Julien Mazières,

Santiago Viteri,

Hélène Senellart,

Jan P. van Meerbeeck,

Jo Raskin,

Niels Reinmuth,

Pierfranco Conté,

Dariusz M. Kowalski,

Byoung Chul Cho,

Jyoti D. Patel,

Leora Horn,

Frank Griesinger,

JiYoun Han,

YoungChul Kim,

GeeChen Chang,

ChenLiang Tsai,

James ChihHsin Yang,

Yuh-Min Chen,

Egbert F. Smit,

Anthonie J. van der Wekken,

Terufumi Kato,

Dilafruz Juraeva,

Christopher Stroh,

Rolf Bruns,

Josef Straub,

Andreas Johne,

J. Scheele,

John V. Heymach,

Xiuning Le

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2004407

Subject(s) - medicine , exon , lung cancer , biopsy , confidence interval , liquid biopsy , exon skipping , population , oncology , gastroenterology , cancer , gene , genetics , alternative splicing , biology , environmental health

A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research